ABBVCLS-7262 is under clinical development by Calico Life Sciences and currently in Phase III for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase III drugs for Amyotrophic Lateral Sclerosis have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how ABBVCLS-7262’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ABBVCLS-7262 overview

ABBVCLS-7262 is under development for the treatment of amyotrophic lateral sclerosis (ALS) and vanishing white matter disease. The drug candidate acts by targeting eukaryotic translation initiation factor 2 subunit beta (EIF2B). It is administered through oral route.

Calico Life Sciences overview

Calico Life Sciences (Calico) is a research and development company. It is operating its business as Calico Group LLC, is a life extension research and development company. It focusses on the discovery, development, and commercialization of therapies for the treatment of diseases of aging including neurodegeneration and cancer. It is focusing on both basic research and the translation of our discoveries into new interventions that can help people live healthier, and maybe longer, lives. It also engaged in research of advanced technologies to increase understanding of the biology that controls lifespan. Calico is headquartered in South San Francisco, California, the US.

For a complete picture of ABBVCLS-7262’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.